Investor Presentaiton

Clinical sensitivity of Shield V2 in a U.S.- based colonoscopy-screened cohort Prospective Study Results CRC Sensitivity N = 45 Specificity N = 1,458 INVESTOR 20 Sensitivity in Stage I/II: DAY 23 Shield CRC V1 - PMA device 84% (38/45) 91% Shield CRC V2 91% (41/45) 91% ECLIPSE CRC Sensitivity N = 65 83% GUARDANT Source: Guardant internal data Specificity N = 6,680 90% V1: 76% (19/25) V2: 88% (22/25) Similar AA performance 126

View entire presentation